!-- notag -->!-- notag -->!-- notag -->
First quarter 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
"We’re off to a good start in 2022 thanks to a strong commitment to our strategy. We’re proud of the progress made in Immunology, with a broad pipeline of 13 potential new treatments in development."
Paul Hudson, CEO at Sanofi